Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.43 |
| ▸ | PDE2A | O00408 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | PDE5A | O76074 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4071323 | 0.87 | PIM1 (0.43) | MAPK14KMT2APIM1PIM2PIK3CA | |
| SCHEMBL6118517 | 0.84 | MAPK14 (0.64) | MAPK14KMT2AHSD17B10ALOX15PDE2A | |
| SCHEMBL4079295 | 0.82 | MAPK14 (0.44) | MAPK14PIM1PIM2TSHRTP53 | |
| SCHEMBL6118911 | 0.82 | MAPK14 (0.61) | MAPK14KMT2AHSD17B10ALOX15PIM1 | |
| SCHEMBL6119012 | 0.81 | PSMD14 (0.41) | MAPK14PIM1PIM2PDE2APDE10A | |
| SCHEMBL6119594 | 0.81 | MAPK14 (0.60) | MAPK14KMT2AHSD17B10ALOX15PIM1 | |
| SCHEMBL4141765 | 0.80 | BRD4 (0.47) | MAPK14PIM1PIM2MAPTPDE5A | |
| SCHEMBL6118923 | 0.80 | MAPK14 (0.59) | MAPK14KMT2AHSD17B10TSHRMAPT | |
| SCHEMBL6118060 | 0.79 | MAPK14 (0.58) | MAPK14KMT2AHSD17B10ALOX15TSHR | |
| SCHEMBL6118506 | 0.79 | MAPK14 (0.58) | MAPK14KMT2AHSD17B10ALOX15PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9199983-B2 | 3-aryl-6-aryl-[1,2,4]triazolo[4,3-α]pyridines as inhibitors of cell proliferation and the use thereof | CAI SUIXIONG (CN) | 2015-12-01 | — | — | US | disclosed |
| US-9199983-B2 | 3-aryl-6-aryl-[1,2,4]triazolo[4,3-α]pyridines as inhibitors of cell proliferation and the use thereof | CAI SUIXIONG (CN) | 2015-12-01 | — | — | US | disclosed |
| US-9199983-B2 | 3-aryl-6-aryl-[1,2,4]triazolo[4,3-α]pyridines as inhibitors of cell proliferation and the use thereof | CAI SUIXIONG (CN) | 2015-12-01 | — | — | US | disclosed |
| US-20130280245-A1 | 3-Aryl-6-aryl-[1,2,4]triazolo[4,3-alpha]pyridines as Inhibitors of Cell Proliferation and the Use Thereof | IMPACT THERAPEUTICS, INC. (CN) | 2013-10-24 | — | — | US | disclosed |
| US-20130280245-A1 | 3-Aryl-6-aryl-[1,2,4]triazolo[4,3-alpha]pyridines as Inhibitors of Cell Proliferation and the Use Thereof | IMPACT THERAPEUTICS, INC. (CN) | 2013-10-24 | — | — | US | disclosed |
| WO-2012065297-A1 | 3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF | IMPACT THERAPEUTICS, INC. (CN) | 2012-05-24 | — | — | WO | disclosed |
| WO-2012065297-A1 | 3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF | IMPACT THERAPEUTICS, INC. (CN) | 2012-05-24 | — | — | WO | disclosed |
| WO-2012065546-A1 | 3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF | IMPACT THERAPEUTICS, INC. (CN) | 2012-05-24 | — | — | WO | disclosed |
| WO-2012065546-A1 | 3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF | IMPACT THERAPEUTICS, INC. (CN) | 2012-05-24 | — | — | WO | disclosed |
| US-8076356-B2 | Triazolopyridinylsulfanyl derivatives as P38 map kinase inhibitors | PFIZER INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-20090239899-A1 | Triazolopyridinylsulfanyl Derivatives As P38 Map Kinase Inhibitors | PFIZER INC. | 2009-09-24 | — | — | US | disclosed |
| EP-1778686-B9 | TRIAZOLOPYRIDINYLSULFANYL DERIVATIVES AS P38 MAP KINASE INHIBITORS | PFIZER LTD (GB) | 2009-07-08 | — | — | EP | disclosed |
| US-7511057-B2 | Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors | PFIZER INC. (US) | 2009-03-31 | — | — | US | disclosed |
| EP-1778686-B1 | TRIAZOLOPYRIDINYLSULFANYL DERIVATIVES AS P38 MAP KINASE INHIBITORS | PFIZER LTD (GB) | 2008-10-29 | — | — | EP | disclosed |
| US-20060035922-A1 | Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors | PFIZER INC. | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035922-A1 | Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors | MAPK1, MAPKAPK5, MAPKAPK3 | MAPK14 24/4885KMT2A 4210/4885HSD17B10 3207/4885 |
| US-20130280245-A1 | 3-Aryl-6-aryl-[1,2,4]triazolo[4,3-alpha]pyridines as Inhibitors of Cell Proliferation and the Use Thereof | MKI67, CCNI, CCNA1 | MAPK14 1211/4885KMT2A 2263/4885HSD17B10 1993/4885 |
| US-20090239899-A1 | Triazolopyridinylsulfanyl Derivatives As P38 Map Kinase Inhibitors | MAPK1, MAPKAPK5, MAPKAPK3 | MAPK14 24/4885KMT2A 4285/4885HSD17B10 3093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.